Week in Review: Rumor: Mindray Medical May Go Private

Mindray Medical, a $3.5 billion Shenzhen medical device company, may be taken private, according to unconfirmed press reports; iKang Healthcare acquired a 70% stake in WA Centers HK Limited, which owns two high-end medical centers in China; Denovo Biopharma, a US-China startup, obtained global rights to a late-stage neuroscience drug from Eli Lilly; Leica Biosystems of Germany gained exclusive rights to distribute Novacyt’s cervical cancer test in Greater China; we published an interview with Michael Yu, CEO of Innovent, a China biosimilar company that raised $100 million in January; Hutchison Chi-Med plans to file two New Drug applications for innovative cancer drugs in 2016; China Wanbang Biopharma successfully completed the toxicology study of a novel treatment for type 2 diabetes: China formally established the Biosimilar Approval process that was issued in draft form last fall; and China's State Council decreed that China hospitals must purchase drugs only from provincial pharmaceutical procurement platforms. More details.... Stock Symbols: (NYSE: MR) (NASQ: KANG) (NYSE: LLY) (AIM: HCM) Share this with colleagues: // //